1. Introduction {#sec1-pathogens-08-00213}
===============

Cytomegalovirus (CMV) is a global herpesvirus that is highly prevalent worldwide. It is a ubiquitous virus with a prevalence of about 100% in both Africa and Asia, and 80% in Europe and North America \[[@B1-pathogens-08-00213]\]. It is a member of the family *Herpesviridae* and genus *Cytomegalovirus* \[[@B2-pathogens-08-00213]\]. CMV is classified as a β-herpesvirus (HHV-5) and considered to be the largest herpesvirus to infect humans, with a genome of nearly 240 kb \[[@B3-pathogens-08-00213]\]. According to the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO), CMV can infect people of all ages; over 50% of adults are infected with CMV by the age of 40, and approximately one in three children are infected with CMV by the age of five in the United States \[[@B4-pathogens-08-00213]\]. Although CMV infection is usually asymptomatic, it could lead to severe outcomes in immunosuppressed individuals, particularly transplant recipients and blood transfusion patients \[[@B5-pathogens-08-00213]\]. CMV disease can mimic a range of different manifestations and pose significant diagnostic challenges, leading to late or inaccurate diagnosis and adverse health outcomes \[[@B6-pathogens-08-00213]\]. Therefore, CMV infection is considered a critical health concern for high-risk populations.

Since CMV is a persistent latent virus, it can manipulate and evade the immune system. Studies have reported multiple genes in CMV that are responsible for immune evasion that profoundly interfere with both the innate and adaptive immunity of the host, thus preventing viral elimination \[[@B7-pathogens-08-00213]\]. Nevertheless, following primary infection, CMV and the host's immune system reach a homeostatic balance, where a lifelong latency is established primarily in cells of the myeloid lineage \[[@B8-pathogens-08-00213]\]. Although reactivation phases can occur, their detection is rare in immunocompetent individuals. The continuous commitment of the immune system to control the viral infection throughout the host's life places a heavy burden on the host's immune system, which could lead to vascular diseases and immune senescence in the elderly \[[@B9-pathogens-08-00213]\]. Significant suppression of the host immune responses against CMV can alter the life-or-death immune surveillance balance, allowing CMV reactivation or primary infection to cause clinical manifestations \[[@B10-pathogens-08-00213],[@B11-pathogens-08-00213],[@B12-pathogens-08-00213],[@B13-pathogens-08-00213],[@B14-pathogens-08-00213]\]. Such cases could be observed with transplantation patients that need to undergo immune suppression therapy. CMV is one of the most frequently reported opportunistic viral pathogens in immune-deficient patients, including solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients \[[@B15-pathogens-08-00213]\]. The uncontrolled viral replication and dissemination can be life-threatening, as it could result in end-organ damage \[[@B1-pathogens-08-00213]\]. Furthermore, CMV is also a leading cause of congenital diseases worldwide, resulting in about 29 congenital conditions as reported from the United States alone \[[@B16-pathogens-08-00213]\].

Notably, there are significant differences in terms of CMV seroepidemiology between different populations and ethnic backgrounds. Since CMV epidemiological studies are scarce in the MENA region, it was of interest to conduct a systemic review to paint a picture of the current status of CMV and evaluate its incidence rate in high-risk sub-populations in the MENA region, namely transplant and transfusion recipients and the newborns.

2. Methods {#sec2-pathogens-08-00213}
==========

2.1. Search Strategy {#sec2dot1-pathogens-08-00213}
--------------------

We conducted a systematic review of all literature published on CMV in the MENA region using four databases: PubMed, Scopus, Science Direct, and Web of Science. The search covered all literature within the databases up to March 2019. The databases were queried with the keywords: "CMV", "Cytomegalovirus", "human herpesvirus 5", and "HHV-5". Each keyword was queried individually with the name of each of the countries in the MENA region. The countries considered as part of the MENA region in this review were: Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Palestine, Qatar, Saudi Arabia, Sudan, Syria, Tunisia, United Arab Emirates, and Yemen. In addition to the names of the countries, the terms "west bank", "Gaza", "UAE", "United Arab Emirates", "Emirates", "KSA", "Middle East", "North Africa", and "MENA" were used to account for alternate names and ensure complete coverage of the region. PubMed, Science Direct, and Web of Science were searched without filters. Scopus was searched while filtering out books, book chapters, and commentaries. All retrieved citations were imported into EndNote X8, and duplicates were removed using the EndNote X8 built-in "Find Duplicates" feature. Finally, the titles and abstracts of the remaining citations were screened to remove any irrelevant articles, such as plant or animal viruses and human viruses other than CMV.

2.2. Study Selection {#sec2dot2-pathogens-08-00213}
--------------------

The following inclusion criteria were used in study selection: (i) published in a peer-reviewed journal, (ii) articles studying the epidemiology CMV in the MENA region, (iii) published as primary research articles, (iv) articles published in English or with an abstract in English, and (v) articles in which CMV is a primary measure or outcome of the study. The peer-review status of the published studies was confirmed using Ulrich's Periodicals Directory (<https://www.ulrichsweb.com/>). Only studies that satisfied all five inclusion criteria were included in this review. Studies were excluded from the review if: (i) the study consisted of a mixture of patients from within and without the MENA region, and it was not possible to differentiate the data, (ii) it is not clear to differentiate the origins of the patients, and (iii) the study investigated multiple viruses, including CMV, and the data could not be differentiated. A schematic of the search strategy and study selection process is shown in [Figure 1](#pathogens-08-00213-f001){ref-type="fig"}.

2.3. Data Extraction and Analysis {#sec2dot3-pathogens-08-00213}
---------------------------------

The studies included in this systematic review were analyzed three times by the same individual to ensure accurate capture of the information. The analyzed data included the country of the study, period of study, number of subjects, type of the study, incidence/prevalence of CMV antibodies or infection, symptoms and complications, proposed risk factors and routes of transmission, as well as treatment and prevention.

3. Results {#sec3-pathogens-08-00213}
==========

3.1. Search Findings {#sec3dot1-pathogens-08-00213}
--------------------

The search yielded 4777 studies, of which 3745 citations remained after removing duplicates ([Figure 1](#pathogens-08-00213-f001){ref-type="fig"}). After screening the titles, abstracts, and keywords, 1724 citations were excluded. The removed citations included irrelevant studies, such as those on animal and plant viruses. The remaining 2021 citations were screened against the eligibility criteria. Of these, 218 studies were removed due to the lack of peer-reviewing, and 1096 were removed for not discussing the epidemiology of CMV in transplant and transfusion patients nor its congenital illness. Furthermore, 422 non-primary research studies were removed (i.e., review articles, editorials, communications, case-reports, etc.), two for being published in languages other than English with no English abstract, and 202 for not having CMV as a measure or outcome of the study. One study was excluded as it was retracted by the authors. Finally, five studies were excluded as they met the exclusion criteria. The remaining 72 studies covered 11 countries (Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Oman, Palestine, Saudi Arabia, Sudan, and Tunisia) over 31 years, from 1988--2019. The highest number of studies was from Iran (*n* = 27), followed by Israel (*n* = 21). No studies meeting the eligibility criteria were found from Algeria, Bahrain, Djibouti, Libya, Morocco, Qatar, Syria, the United Arab Emirates, and Yemen.

3.2. Epidemiological Findings {#sec3dot2-pathogens-08-00213}
-----------------------------

The reviewed studies covering CMV incidence in transplant recipients included renal transplants (*n* = 15), hematopoietic stem cell transplant (HSCT; *n* = 4), bone marrow transplants (BMT; *n* = 3), liver transplants (*n* = 3), and coronary artery bypass graft (*n* = 1). Country-wise, the majority of the studies were from Iran (*n* = 19). The remaining studies were published from Saudi Arabia (*n* = 4), Egypt (*n* = 2), Israel (*n* = 2), Kuwait (*n* = 2), Iraq (*n* = 1), Jordan (*n* = 1), Oman (*n* = 1), Sudan (*n* = 1), and Tunisia (*n* = 1). Overall, CMV infection among transplant recipients has been reported with an incidence ranging from 1.22% to 72%, regardless of prophylactic treatment. On the other hand, the anti-CMV IgG seroprevalence rate ranged between 8.7% and 99.2% (SD = 38.95), being mostly reported in Iran ([Table 1](#pathogens-08-00213-t001){ref-type="table"}). Fewer studies reported the IgM seroprevalence (*n* = 3), which ranged from 1.6% to 9.6%. The design and criteria to describe CMV disease in these studies were inconsistent ([Table 1](#pathogens-08-00213-t001){ref-type="table"}). Furthermore, multiple studies reported an association between increased incidences of CMV and advanced age. Other risk factors that were found include anti-rejection therapy, previous exposure to CMV, serological mismatch between the donor and recipient, as well as, several immunological determinants. However, there was a lack of CMV epidemiological studies from several countries in the region (Algeria, Bahrain, Djibouti, Lebanon, Libya, Morocco, Palestine, Qatar, Syria, the UAE, and Yemen), rendering the actual incidence of CMV across the region undetermined. As for congenital CMV, the studies were also inconsistent with their diagnosis and reporting of the results. Therefore, accurate incidence/prevalence data could not be deduced. Furthermore, the majority of the studies report infected cases with no incidence/prevalence data. The 38 studies with epidemiological information included in this review came from Israel (*n* = 19), Iran (*n* = 9), Iraq (*n* = 2), Egypt (*n* = 2), Kuwait (*n* = 1), and Oman (*n* = 1).

4. Discussion {#sec4-pathogens-08-00213}
=============

To the best of our knowledge, this is the first systematic review study that investigated the epidemiology and status of CMV in immunocompromised patients in the MENA region. A total of 72 out of 3745 screened studies, covering 11 countries, were examined transplantation and blood transfusion recipients as well as the congenital CMV.

4.1. CMV in Transplantation Recipients in the MENA Region {#sec4dot1-pathogens-08-00213}
---------------------------------------------------------

CMV infects up to 60--100% of people in adulthood, and it is one of the main agents involved in infectious complications after transplantation \[[@B17-pathogens-08-00213]\]. It threatens the survival of transplant recipients and the function of the transplanted organ. Graft rejection and graft-versus-host disease (GVHD) are multisystem disorders that are common complications of transplantation. GVHD occurs when immune cells transplanted from a non-identical donor (the graft) recognize the transplant recipient (the host) as foreign, thereby initiating an immune reaction that causes disease in the transplant recipient \[[@B18-pathogens-08-00213]\]. A less well-established risk factor for GVHD is the CMV status of the donor and host \[[@B19-pathogens-08-00213],[@B20-pathogens-08-00213],[@B21-pathogens-08-00213],[@B22-pathogens-08-00213],[@B23-pathogens-08-00213]\]. Fortunately, it rarely results in mortality, with only one study reporting severe effects \[[@B20-pathogens-08-00213]\]. Generally, infection with CMV results in systemic viral syndrome, as shown in [Table 1](#pathogens-08-00213-t001){ref-type="table"}. The main manifestations are characterized by fever, malaise, vomiting, leukopenia, thrombocytopenia, and elevated liver enzymes. Upper digestive tract symptoms and pain are also common \[[@B23-pathogens-08-00213],[@B24-pathogens-08-00213],[@B25-pathogens-08-00213],[@B26-pathogens-08-00213]\]. Furthermore, respiratory illnesses, including pneumonia, have been reported in a few studies \[[@B24-pathogens-08-00213],[@B27-pathogens-08-00213],[@B28-pathogens-08-00213],[@B29-pathogens-08-00213]\]. Few studies reported other illnesses including hepatitis \[[@B25-pathogens-08-00213]\], urinary tract infection \[[@B24-pathogens-08-00213]\], rhinitis \[[@B28-pathogens-08-00213],[@B29-pathogens-08-00213]\], skin conditions \[[@B23-pathogens-08-00213],[@B24-pathogens-08-00213]\], and rarely, aortic plaques \[[@B30-pathogens-08-00213]\]. The disease caused by post-transplant CMV occurs due to the transplantation of an infected organ, reactivation of latent infection, or after primary infection in seronegative transplant patients \[[@B31-pathogens-08-00213],[@B32-pathogens-08-00213]\]. The occurrence of disease caused by CMV in transplanted patients varies according to the organ transplanted, the serological match between recipient and donor, the immunosuppressive drugs used, and, most importantly, the interference of any additional diseases \[[@B17-pathogens-08-00213]\]. The incidence of CMV infection is 50% to 75% in patients undergoing heart-lung or lung transplantation and 50% in patients undergoing pancreas or kidney-pancreas transplantation. The incidence of CMV infection is 9% to 23% after heart transplantation, and 22% to 29% after liver transplantation \[[@B33-pathogens-08-00213]\]. In addition, 30% of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) and approximately 5% of patients undergoing autologous HSCT develop CMV disease \[[@B34-pathogens-08-00213]\]. Moreover, a study on CMV infections in the context of HSCT showed that 68% of pediatric patients who received umbilical cord blood transplantation were CMV seropositive \[[@B34-pathogens-08-00213]\].

Multiple studies investigated the association between the risk of CMV infection in transplant patients' and their demographics, including age, gender, and source of transplantation; however, results were inconsistent. A recently published study from Iran reported that CMV was diagnosed in 178 out of 725 (24.6%) kidney recipients, and showed that the incidence of CMV disease in kidney transplant patients within the age group 41--60 was four-fold more compared to those under 20 years old \[[@B27-pathogens-08-00213]\]. Similarly, a study conducted on HSCT in Iran revealed a positive correlation between the age of the recipients and CMV antigenemia \[[@B23-pathogens-08-00213]\]. On the other hand, other studies, such as in Saudi Arabia, failed to show this correlation \[[@B35-pathogens-08-00213]\]. These observations, along with those from other countries around the globe \[[@B36-pathogens-08-00213]\], indicate that age was a risk factor for CMV infection, especially in transplant patients \[[@B37-pathogens-08-00213],[@B38-pathogens-08-00213]\]. For instance, a study reported that the risk of death was significantly increased in patients \>38 years old, who underwent transplantation with peripheral blood, with an unrelated or mismatched donor, and who developed a CMV infection \[[@B39-pathogens-08-00213]\]. In addition, a study conducted on 200 allografted patients showed that recipients aged over 16 years were found to be at significant risk of CMV reactivation compared with younger patients (*p* = 0.007) \[[@B40-pathogens-08-00213]\].

In addition to age, several other factors have been identified in association with CMV incidence in SOT and HSCT recipients. One of the most significant risk factors is the extensive use of immunosuppressive drugs for patients undergoing organ transplantation. For instance, Taherimahmoudi et al. suggested that immunosuppression therapy using lymphocyte-depleting antibodies, namely anti-thymocyte globulin (ATG) therapy, is considered as one of the leading risk factors for CMV disease \[[@B41-pathogens-08-00213]\]. Charfeddine et al. reported that 12 out of the 16 patients who received kidney transplants suffered from CMV infections. Additionally, 6 out of those 12 patients developed acute rejection episodes due to CMV infection after administrating additional immunosuppressive treatment \[[@B21-pathogens-08-00213]\]. Such high frequency of infection was attributed to intensive antirejection therapy (including azathioprine, prednisone, cyclosporine, and ATG), among other factors such as previous exposure to CMV prior to transplantation \[[@B42-pathogens-08-00213]\], serological mismatch between both donor and recipient (e.g., CMV-negative recipients (R−)) received grafts from CMV-positive donors (D+)), and immune system factors.

Several immune correlates were identified as predictors for post-transplant CMV infection. One of them is mannose-binding-lectin (MBL), an innate humoral immunity protein that is important for pathogen opsonization and activation of complement pathways. One study documented a positive correlation between the infection and low levels of MBL. MBL deficiency compromises the innate immune response, resulting in a higher risk of developing post-transplant CMV disease and increasing the necessity of prophylactic treatment \[[@B43-pathogens-08-00213]\]. Other factors include CD 56^+^ T-cell levels, HLA mismatch, and GVHD. CD56^+^ T-cells (also known as NK-like T cells or cytokine-induced killer cells) have a potent cytotoxic effect on CMV, and a significant increase in their levels in renal transplant patients is suggestive of current CMV infection \[[@B44-pathogens-08-00213]\]. As for HLA, CMV disease was found to be influenced by more than one HLA allele mismatch \[[@B45-pathogens-08-00213]\]. Moreover, some studies have shown that specific alleles can promote or protect from post-transplant CMV disease. For instance, Khalifa et al. reported that 33.3% of CMV pp65 antigenemia positive patients in SOT have the HLA-A \* 02 genotype, while patients with HLA-A \* 01 (57.1%) had a protective effect against CMV infection \[[@B46-pathogens-08-00213]\]. Another study showed that kidney recipients with the HLA-B44 allele are more susceptible to CMV infection after transplantation, while carriers of the HLA-B8 allele are naturally protected from CMV infection \[[@B47-pathogens-08-00213]\]. Furthermore, a study showed that specific single-nucleotide polymorphisms (SNPs) in the loci of co-stimulatory molecules CTLA4 and CD28, which function in the regulation of T-cell activation, influence active CMV infection in kidney transplant patients \[[@B48-pathogens-08-00213]\]. Overall, these studies suggest the use of HLA typing as a predictor for CMV infection within the context of personalized medicine for prophylactic post-transplantation treatment.

The high risk of CMV infection and transmission through organ transplantation is universal. The prevalence across the globe ranges from 45% in developed countries to near 100% in developing countries \[[@B1-pathogens-08-00213]\]. The health burden of CMV infection and its manifestations seen in the MENA region is similar to that seen in other populations \[[@B49-pathogens-08-00213],[@B50-pathogens-08-00213]\]. Even though the risk is high for transplant patients in the MENA region, only a few studies suggested screening for CMV in donors. For instance, in Saudi Arabia, screening for CMV and other pathogens before transplantation, especially in HSCT, was found to improve patient safety and mitigate the risk of accidental CMV infection \[[@B51-pathogens-08-00213]\]. One of the suggested approaches to protect from post-transplant CMV infection is the treatment with antibodies targeting CMV antigens (pp. 28, 150), which was shown to be effective in kidney transplantation \[[@B52-pathogens-08-00213]\]. On the other hand, Shibolet et al. demonstrated the development of late CMV disease and the occurrence of rejection episodes in liver transplantation recipients, regardless of the early use of antiviral prophylaxis \[[@B29-pathogens-08-00213]\]. In conclusion, due to the potential abnormalities associated with CMV infection and various morbidities, the establishment of preventive measures, especially vulnerable populations, including transplant recipients, is required.

4.2. CMV in Blood Transfusion Recipients in the MENA Region {#sec4dot2-pathogens-08-00213}
-----------------------------------------------------------

CMV infection not only compromises transplantation but can also compromise the effectiveness of blood-transfusions, leading to transfusion-transmitted CMV infection, especially in immunocompromised patients. Transfusion-transmitted CMV infection occurs mainly due to the re-activation of the latent virus in WBCs. Many studies were performed to assess the seropositivity rates in different MENA region countries. Only a few studies, conducted mainly in Iran and Egypt, reported CMV infection after blood transfusion in the MENA region. The type of transfusion mainly discussed by the articles included in this review is whole blood transfusion; this is because most of the patients that need regular and frequent whole blood donations are anemic and thalassemic patients such as transfusion of other blood products like plasma transfusion, which is safer since most of the time it is autologous. That is why all research done on CMV seroprevalence was about patients with thalassemia who received multiple types of blood from different donors that could have been positive for the virus. A recent study in Mashhad, Iran, showed that out of 1008 blood samples that were tested for CMV antibodies, 99.2% were found to be positive \[[@B53-pathogens-08-00213]\]. In another study from Iran, Sepehrvand et al. reported that the high incidence of CMV antibodies that were present in transfusion patients' blood is a result of receiving blood from CMV infected donors \[[@B54-pathogens-08-00213]\].

Furthermore, Mahmoud et al. showed that frequent blood transfusions among thalassemic children in Upper Egypt exposed them to a higher risk of transfusion-transmitted infections, including CMV. In this study, high rates of CMV infections were reported in children receiving a blood transfusion, and the infection was positively correlated with increasing age and the duration of the thalassemia \[[@B55-pathogens-08-00213]\]. These high rates of CMV infections are attributed to the high CMV seroprevalence among blood donors in Egypt, as reported by Gawad et al. In their study, 96.6% of blood donors (out of 88 tested blood samples) were CMV seropositive \[[@B56-pathogens-08-00213]\].

Overall, these findings demonstrate a high rate of prevalence of CMV infections in the MENA region, and as such, posing serious implications for the blood transfusion practices if proper screening measures are not implemented. High CMV positivity in transfusion patients, highlighted clearly in some of MENA countries ([Table 1](#pathogens-08-00213-t001){ref-type="table"}), assures that there is a crucial need for mitigation plans to reduce CMV transmission in transfusion patients.

4.3. Congenital CMV (cCMV) in the MENA Region {#sec4dot3-pathogens-08-00213}
---------------------------------------------

The reviewed studies (*n* = 38) documented a total of 1271 fetuses and infants from eight countries. The subjects were either confirmed CMV cases with vertical transmission of the virus or unconfirmed seropositive cases \[[@B71-pathogens-08-00213],[@B72-pathogens-08-00213],[@B73-pathogens-08-00213],[@B74-pathogens-08-00213],[@B75-pathogens-08-00213],[@B76-pathogens-08-00213],[@B77-pathogens-08-00213]\]. Clinical CMV manifestations were assessed either with antenatal ultrasound or postnatal cCMV associated complications. The majority of the studies came from Israel (*n* = 19), where the primary clinical features included abnormal ultrasound, severe brain dysmorphology (mainly in the first and second trimesters), hearing abnormalities, as well as occult CNS symptoms that are associated with neurologic sequelae, abortion, premature deaths, and congenital malformations \[[@B71-pathogens-08-00213],[@B74-pathogens-08-00213],[@B78-pathogens-08-00213],[@B79-pathogens-08-00213],[@B80-pathogens-08-00213],[@B81-pathogens-08-00213],[@B82-pathogens-08-00213],[@B83-pathogens-08-00213],[@B84-pathogens-08-00213],[@B85-pathogens-08-00213],[@B86-pathogens-08-00213]\]. On the other hand, some studies reported asymptomatic cCMV infections \[[@B87-pathogens-08-00213],[@B88-pathogens-08-00213]\].

In terms of disease morbidity, one of the common complications of cCMV observed in the MENA region is abnormal brain sonography. Hadar et al. reported a 67% occurrence of abnormal brain sonography in infants born to mothers with primary maternal infection, and 8.3% in infants born to mothers with non-primary infection \[[@B89-pathogens-08-00213]\]. Another common complication of cCMV is hearing loss. A retrospective study in Israel correlated early cCMV infection with hearing loss \[[@B79-pathogens-08-00213]\]. In addition, cCMV could lead to hepatic damage, including hepatitis and cholestatic disease \[[@B88-pathogens-08-00213]\]. The frequency of which (6.6%) was found to be less than was previously expected and is far out shadowed by CNS involvement (84.6%) and hearing loss (53.8%) \[[@B88-pathogens-08-00213]\]. In all cases, however, rapid antiviral treatment showed improvement in symptoms, albeit over prolonged periods \[[@B79-pathogens-08-00213],[@B88-pathogens-08-00213]\]. As for mortality, higher rates were found in association with primary cCMV infections compared to recurrent infections, and abortions were reported at all pregnancy stages \[[@B73-pathogens-08-00213],[@B90-pathogens-08-00213]\]. Jahromi et al. found that there is an association between seropositivity and abortion rate \[[@B91-pathogens-08-00213]\].

Nevertheless, there is substantial variability in the definitions of symptomatic and asymptomatic cCMV infection, study designs, and the methods of determining CMV infection. This variability, along with the variability in study design and detection methods, created difficulty in assessing the overall status of cCMV in the region ([Table 2](#pathogens-08-00213-t002){ref-type="table"}). Similar variations are also seen in the US and Germany, suggesting complicated disease manifestations, depending on the genetic, health, and nourishment status of the infants and their mothers \[[@B92-pathogens-08-00213],[@B93-pathogens-08-00213],[@B94-pathogens-08-00213],[@B95-pathogens-08-00213]\]. Still, the incidence rate of cCMV in the MENA region seems to be higher than in other populations. Schlesinger et al. reported an incidence of 945/135,000 (0.7%) births in 2005 in Israel \[[@B96-pathogens-08-00213],[@B97-pathogens-08-00213]\]. This incidence rate is similar to that found in the United States (0.6--0.7%) \[[@B98-pathogens-08-00213]\]. The rate is, however, higher than in Europe, to which Israel's healthcare system is more similar. For instance, Sweden and the UK have incidence rates of 4.6/1000 births (0.46%) and 3.2/1000 births (0.32%), respectively, and a decades-long prospective study in Denmark found the incidence rate to be 0.4% \[[@B99-pathogens-08-00213],[@B100-pathogens-08-00213]\].

4.4. Laboratory Diagnosis of CMV in the MENA Region {#sec4dot4-pathogens-08-00213}
---------------------------------------------------

CMV diagnosis was traditionally performed by serologic testing and viral cultures from multiple samples; however, molecular diagnosis is currently the standard \[[@B116-pathogens-08-00213]\]. A similar trend can be seen in the MENA region with the diagnosis of CMV. In the 1980s, culture and serological methods were used to detect CMV. The trend moved towards molecular testing, with polymerase chain reaction (PCR) becoming more prominent over time. In the reviewed literature, multiple diagnostic laboratory tools were used, including serology, PCR, antigenemia assays, immunohistochemistry, and culture.

Serological methods indirectly provide evidence of current or prior infection by detection of antibodies in serum. The presence of anti-CMV IgM antibodies can be used to diagnose a recent or acute infection, or at least a fourfold increase in IgG antibody titer in subsequent specimens obtained two to four weeks apart \[[@B116-pathogens-08-00213]\]. However, IgM antibodies can persist for several months, leading to false-positive results for acute infection \[[@B117-pathogens-08-00213]\]. Thus, a definite diagnosis of CMV infection cannot be obtained from serological tests. Nevertheless, serological antibody detection remains a cost-effective screening tool. Serological methods alone, or in conjunction with other methods, are employed in the MENA region to screen for CMV before and after transplantation \[[@B23-pathogens-08-00213],[@B47-pathogens-08-00213],[@B52-pathogens-08-00213],[@B57-pathogens-08-00213],[@B63-pathogens-08-00213],[@B68-pathogens-08-00213],[@B70-pathogens-08-00213],[@B118-pathogens-08-00213],[@B119-pathogens-08-00213],[@B120-pathogens-08-00213],[@B121-pathogens-08-00213],[@B122-pathogens-08-00213],[@B123-pathogens-08-00213],[@B124-pathogens-08-00213]\]. Moreover, serology is used in Israel to screen pregnant women for CMV infection. Although no formal regulations exist, still, most hospitals perform routine screening for anti-CMV antibodies using the criteria mentioned earlier to establish a diagnosis \[[@B74-pathogens-08-00213],[@B125-pathogens-08-00213],[@B126-pathogens-08-00213]\]. Once the presence of CMV is established in the mother, congenital CMV is diagnosed either by pre-natal amniocentesis followed by culture or PCR, or by PCR or antigenemia assays in the urine of the infant \[[@B73-pathogens-08-00213],[@B75-pathogens-08-00213],[@B76-pathogens-08-00213],[@B78-pathogens-08-00213],[@B80-pathogens-08-00213],[@B104-pathogens-08-00213],[@B108-pathogens-08-00213],[@B127-pathogens-08-00213]\].

In recent years, PCR has become prominent in CMV testing in the MENA region. PCR is highly sensitive and specific. However, its main drawback is that it cannot differentiate between latent and active virus \[[@B116-pathogens-08-00213]\]. Additionally, there is variability in the viral loads obtained by different laboratories for the same specimen. In response, the WHO developed an international quantitative standard to standardize measurements and facilitate studies to correlate viral load with the development of the disease \[[@B128-pathogens-08-00213],[@B129-pathogens-08-00213]\]. Nevertheless, the variability among assays continues to exist due to differences in specimen types, DNA extraction methods, as well as the PCR protocol \[[@B130-pathogens-08-00213],[@B131-pathogens-08-00213],[@B132-pathogens-08-00213]\]. Currently, PCR is commonly used in the MENA region for the diagnosis of CMV. It is used to test for congenital CMV in amniotic fluid or urine \[[@B73-pathogens-08-00213],[@B75-pathogens-08-00213],[@B76-pathogens-08-00213],[@B78-pathogens-08-00213],[@B80-pathogens-08-00213],[@B104-pathogens-08-00213],[@B108-pathogens-08-00213],[@B127-pathogens-08-00213]\], to monitor CMV infection after transplant \[[@B41-pathogens-08-00213],[@B62-pathogens-08-00213],[@B133-pathogens-08-00213],[@B134-pathogens-08-00213],[@B135-pathogens-08-00213],[@B136-pathogens-08-00213]\], as well as end-organ testing when a specific organ is affected, such as HIV associated CMV retinitis \[[@B137-pathogens-08-00213]\].

Finally, CMV antigenemia, immunohistochemistry, and culture methods are used in the MENA region as a definite diagnosis of CMV infection. Antigenemia is used in the diagnosis of congenital CMV and the monitoring of viremia in transplant patients. The assay is based on the detection of the CMV pp65 protein in peripheral blood leukocytes. Their advantage over measuring anti-CMV antibodies and PCR is that it can detect the active virus, correlating the result of the assay with viremia \[[@B116-pathogens-08-00213]\]. Immunohistochemistry assays use labeled antibodies directed towards CMV antigens (early antigen, immediate early antigens, pp65, and late antigen) and are visualized under the microscope. A positive result in immunohistochemistry indicates the presence of CMV \[[@B138-pathogens-08-00213]\]. In the MENA region, this method was only used in studies of tissue biopsies of invasive CMV infections in the case of cancer \[[@B139-pathogens-08-00213],[@B140-pathogens-08-00213],[@B141-pathogens-08-00213],[@B142-pathogens-08-00213]\]. This usage is in line with the international consensus for the diagnosis of CMV in invasive tissue disease \[[@B138-pathogens-08-00213]\]. As for culture, conventional methods have been replaced by the more rapid shell-vial cultures \[[@B116-pathogens-08-00213]\]. Shell-vial culture involves the centrifugation of a patient specimen onto a cell monolayer in a vial, which speeds up the time to the result. The virus is then detected in the monolayer using fluorescent antibodies. The MENA region also sees the same trend of replacing traditional cell culture with shell-vial cultures. In Israel, shell-vial culture is the method in use for the diagnosis of congenital CMV from urine specimens from the infants \[[@B72-pathogens-08-00213],[@B89-pathogens-08-00213],[@B102-pathogens-08-00213],[@B118-pathogens-08-00213],[@B143-pathogens-08-00213],[@B144-pathogens-08-00213]\].

While we summarized in this review the techniques used in CMV diagnosis, they do not necessarily reflect the status of CMV diagnosis in the region. The reviewed studies did not cover all the countries in the MENA region; thus, a more in-depth analysis was not possible. Nevertheless, the information does reflect the availability of the diagnostic tools in the region during the study period. However, even though the diagnostic tools are available and widely used in the region, there is no information on country-wide screening guidelines and policies. Instead, hospitals implement their own practices and guidelines on screening.

5. Conclusions {#sec5-pathogens-08-00213}
==============

The literature search yielded a total of 72 primary research articles covering 11 out of the 21 MENA countries over 31 years. The studies on transplant and transfusion recipients reported the incidence of CMV with uncertainty about the disease. Although infection with CMV virus is common among graft recipients in this region (up to 77%), the actual rate of clinically confirmed CMV disease was unclear as most of the studies depend solely on seroprevalence reports. Multiple other studies exist outside of those included in this review; however, they do not measure the incidence of CMV. Although some studies assessed the frequency of transplantation, the CMV incidence as a critical outcome was not reported in many of the studies. Similarly, with blood transfusion, studies report CMV seroprevalence with no clear indication of clinical burden. The same can be observed with cCMV, where substantial variability in cCMV reporting criteria leads to a less-than-accurate picture about the status of cCMV in the MENA region. The low number of published articles, the low number of reporting countries, the inconsistency in measurement and detection protocols, as well as the variability in endpoint evaluation of the clinical illness, are all factors that limited the ability to generalize the information across the region. Thus, there is an incessant need to conduct well-designed studies under the umbrella of the WHO to estimate the burden of CMV disease on transplant recipients in the MENA region and to standardized both the prophylactic and preemptive treatment and predict the subsequent morbidity and mortality.
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pathogens-08-00213-t001_Table 1

###### 

Cytomegalovirus (CMV) in transplant and transfusion recipients in the MENA region.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country        Study Type              Study Period   Transplant Type                       No. of Patients   Seroprevalence                                       Median Time of Detection after TX          Symptoms and Complications                                                                                                                                                              Reference
  -------------- ----------------------- -------------- ------------------------------------- ----------------- ---------------------------------------------------- ------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------
  Iran           Retrospective study     1984--2002     Kidney                                1925              5.2%                                                 1 to 9 months                              Elevated serum creatinine, fever, thrombocytopenia, nausea, vomiting, elevated alkaline phosphatase, leukocytosis, leukopenia, rarely pneumonia, conjunctivitis, vascular dermatitis.   Pour-Reza-Gholi et al., 2005 \[[@B28-pathogens-08-00213]\]

  Iran           Retrospective study     1984--2007     Kidney                                2211              2.1%                                                 NM                                         1 patient died, 3 lost their allograft function                                                                                                                                         Nemati et al., 2008 \[[@B20-pathogens-08-00213]\]

  Iran           Cross-sectional study   1991--2010     Kidney                                96                37.5%                                                NM                                         NM                                                                                                                                                                                      Khameneh et al., 2013 \[[@B57-pathogens-08-00213]\]

  Tunisia        Cohort study            1994--1998     Kidney                                18                72%                                                  First 30 days                              Six patients had acute rejection                                                                                                                                                        Charfeddine et al., 2002 \[[@B21-pathogens-08-00213]\]

  Iran           Retrospective study     1996--2007     Liver                                 22                4.5%                                                 NM                                         NM                                                                                                                                                                                      Yaghobi et al., 2010 \[[@B58-pathogens-08-00213]\]

  Saudi Arabia   Cross-sectional         1996--2014     Donors                                263               13.2%                                                NM                                         NM                                                                                                                                                                                      Alsuhaibani et al., 2015 \[[@B51-pathogens-08-00213]\]

  Iran           Retrospective study     1998--2014     Kidney                                725               24.6%                                                First 5 months                             Weakness, fever, respiratory symptoms                                                                                                                                                   Babazadeh et al., 2017 \[[@B27-pathogens-08-00213]\]

  Kuwait         Cohort Study            2000--2005     Kidney                                54                11.11%                                               NM                                         NM                                                                                                                                                                                      Madi et al., 2011 \[[@B59-pathogens-08-00213]\]

  Saudi Arabia   Retrospective study     2000--2006     Kidney                                689               3.6%                                                 NM                                         Fever, malaise, leukopenia                                                                                                                                                              Basri et al., 2007 \[[@B60-pathogens-08-00213]\]

  Iran           cohort study            2001--2002     BMT                                   15                53.5%                                                4 weeks                                    Fever; gastrointestinal; skin lesion; retinitis, pneumonia, UTI                                                                                                                         Behzad-Behbahani et al., 2004 \[[@B24-pathogens-08-00213]\]

  Egypt          Retrospective study     2001--2003     BMT                                   28                39%                                                  NM                                         NM                                                                                                                                                                                      Zekri et al., 2004 \[[@B42-pathogens-08-00213]\]

  Iran           Cross-sectional         2002--2004     Kidney                                179               17.6%                                                NA                                         Fever, malaise, arthralgias, myalgia, leukopenia and/or thrombocytopenia, or tissue-invasive disease                                                                                    Pourmand et al., 2007 \[[@B61-pathogens-08-00213]\]

  Iran           Retrospective study     2002--2006     BMT                                   104               IgG seroprevalence: 8.7% IgM Seroprevalence: 9.6%    1st--10th weeks                            NA                                                                                                                                                                                      Ramzi et al., 2009 \[[@B62-pathogens-08-00213]\]

  Saudi Arabia   Retrospective study     2002--2007     Cord blood                            73                58.9%                                                NM                                         NM                                                                                                                                                                                      Al-Hajjar et al., 2011 \[[@B34-pathogens-08-00213]\]

  Israel         Cohort study            2003           Liver                                 81                8.5%                                                 NA                                         Fever, disturbed liver functions in all patients, one patient had concurrent CMV pneumonitis and one CMV retinitis                                                                      Shibolet et al., 2003 \[[@B29-pathogens-08-00213]\]

  Iran           Retrospective study     2005--2008     Kidney                                925               IgG seroprevalence: 100%                             NA                                         NA                                                                                                                                                                                      Saghafi et al., 2009 \[[@B63-pathogens-08-00213]\]

  Saudi Arabia   Retrospective study     2005--2011     HSCT                                  82                1.22%                                                NA                                         NA                                                                                                                                                                                      Al-Sweedan et al., 2017 \[[@B64-pathogens-08-00213]\]

  Jordan         Retrospective study     2005--2013     HSCT                                  72                31%                                                  23 days (12--31) post-transplantation      None of the patients developed CMV disease                                                                                                                                              Hussain et al., 2015 \[[@B65-pathogens-08-00213]\]

  Sudan          Retrospective study     2006           Kidney                                98                32.7%                                                2--3 months after kidney transplantation   Fever, diarrhea, hepatitis, neutropenia and/or thrombocytopenia.                                                                                                                        Enan et al., 2011 \[[@B25-pathogens-08-00213]\]

  Iran           Prospective study       2006--2008     Kidney                                40                Infection ^a^: 82.5%\                                Infection: 4.7 weeks Disease: 11 weeks     CMV disease, nine patients manifested with elevated serum creatinine values and one, elevated liver enzymes                                                                             Taherimahmoudi et al., 2009 \[[@B41-pathogens-08-00213]\]
                                                                                                                Disease ^b^: 25%                                                                                                                                                                                                                                                                        

  Iran           Retrospective study     2006--2013     Liver                                 145               32%                                                  12 to 445 days post transplantation        Only 1 patient (2%) developed CMV disease                                                                                                                                               Davoudi et al., 2014 \[[@B66-pathogens-08-00213]\]

  Oman           Retrospective study     2006--2015     Kidney                                703               14.5%                                                21 months (15 days--84 months)             Fever, diarrhea, pneumonitis, lymphopenia, anemia, thrombocytopenia                                                                                                                     Siddiqui et al., 2017 \[[@B26-pathogens-08-00213]\]

  Iraq           Cross-sectional study   2007--2008     Kidney                                43                97.7%                                                NA                                         NA                                                                                                                                                                                      Al-Alousy et al., 2011 \[[@B67-pathogens-08-00213]\]

  Iran           Cross-sectional         2007--2010     Transfusion                           96                IgG Seroprevalence: 77.4%\                           NA                                         NA                                                                                                                                                                                      Sepehrvand et al., 2010 \[[@B54-pathogens-08-00213]\]
                                                                                                                IgM seroprevalence: 7.1%                                                                                                                                                                                                                                                                

  Israel         Retrospective study     2007--2012     HSCT                                  121               61%                                                  NA                                         First CMV infection with myeloablative conditioning and acute GVHD                                                                                                                      Cohen et al., 2015 \[[@B22-pathogens-08-00213]\]

  Iran           Prospective study       2008           Kidney                                68                70.6%                                                NA                                         19 cases of acute rejection                                                                                                                                                             Khameneh et al., 2008 \[[@B68-pathogens-08-00213]\]

  Iran           Cross section           2009--2010     Kidney                                91                34.4%                                                30 days                                    NA                                                                                                                                                                                      Nasiri et al., 2011 \[[@B69-pathogens-08-00213]\]

  Iran           Retrospective study     2011--2013     HSCT                                  126               34%                                                  40 days (3--77) after transplantation      GI, dermal symptoms with hepatic involvement\                                                                                                                                           Valadkhani et al., 2016 \[[@B23-pathogens-08-00213]\]
                                                                                                                                                                                                                \* 9 cases develop GVHD                                                                                                                                                                 

  Iran           Case-control study      2012--2013     coronary artery bypass graft (CABG)   110               CMV DNA in Cases: 14.5% CMV DNA in Controls: 4%      NM                                         CMV in aortic plaques associated with increased risk of atherosclerosis                                                                                                                 Heydar et al., 2015 \[[@B30-pathogens-08-00213]\]

  Iran           Cross-sectional         2012--2013     Kidney Graft                          96                19.8%                                                NM                                         NM                                                                                                                                                                                      Khameneh et al., 2013 \[[@B57-pathogens-08-00213]\]

  Iran           Cross-sectional         2012--2013     Donors                                1008              IgG seroprevalence: 99.2% IgM seroprevalence: 1.6%   NA                                         NA                                                                                                                                                                                      Safabakhsh et al., 2013 \[[@B53-pathogens-08-00213]\]

  Kuwait         Retrospective study     2012--2014     Kidney                                1168              15.4%                                                NA                                         41% have graft rejection, 34.4% develop systemic CMV disease, 24.5% develop CMV syndrome, 1.6% died                                                                                     Madi et al., 2015 \[[@B19-pathogens-08-00213]\]

  Iran           Cohort study            2013           Kidney                                82                49%                                                  Four months post-transplantation           The study aimed to correlate CMV infection with decreasing in vitamin D level.                                                                                                          Saber et al., 2015 \[[@B70-pathogens-08-00213]\]

  Egypt          Cross-sectional         2016           Donors                                88                IgG Seroprevalence: 96.6%                            NA                                         NA                                                                                                                                                                                      Gawad et al., 2016 \[[@B56-pathogens-08-00213]\]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* NM: Not mentioned; NA: Not applicable, due to the subjects being healthy individuals. ^a^: Infection was defined by the presence of anti-CMV IgG, anti-CMV IgM, CMV DNA, or a positive result for the pp65 antigenemia assay. ^b^: Disease was defined by the presence of symptoms.
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###### 

CMV in the MENA region.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country     Study Type                                             Study Period                 No. of Patients                                                                                                         CMV Results                                                                                                                                          Symptoms and Complications                                                  Reference
  ----------- ------------------------------------------------------ ---------------------------- ----------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------- ----------------------------------------------------------------
  Kuwait      Experimental study                                     1988                         575 infants                                                                                                             2.6% positive IgM                                                                                                                                    NM                                                                          El-Mekki et al., 1988 \[[@B101-pathogens-08-00213]\]

  Israel      Retrospective study                                    1993--1997                   63 pregnant women                                                                                                       34.8% showed vertical transmission                                                                                                                   Abnormal ultrasound, neurologic sequelae                                    Lipitz et al., 1997 \[[@B76-pathogens-08-00213]\]

  Iraq        Prospective-follow up until delivery                   1999                         60 pregnant women                                                                                                       10% CMV IgM in cord blood                                                                                                                            Congenital malformations, microcephaly                                      Al-Ali et al., 1999 \[[@B86-pathogens-08-00213]\]

  Israel      Retrospective study                                    1999--2008                   59 primary Periconceptional CMV infection                                                                               18.6% CMV infections                                                                                                                                 NM                                                                          Hadar et al., 2010 \[[@B73-pathogens-08-00213]\]

  Israel      Retrospective study                                    2001--2012                   9845 infants                                                                                                            0.57% CMV infection                                                                                                                                  Abnormal hearing                                                            Barkai et al., 2014 \[[@B81-pathogens-08-00213]\]

  Iran        case-control study                                     2002--2003                   95 with sensory hearing loss                                                                                            34.6% CMV infection                                                                                                                                  Sensorineural hearing loss                                                  Pasternak et al., 2018 \[[@B102-pathogens-08-00213]\]

  Iran        This case-control study                                2003--2004                   250 women with a history of abortion and 200 matched with no abortion                                                   5% positive for CMV                                                                                                                                  Abortion                                                                    Jahromi et al., 2010 \[[@B91-pathogens-08-00213]\]

  Israel      A prospective study                                    2005                         70 infants who received breast milk from seropositive mothers                                                           5.7% acquired CMV by the second or third week of pregnancy                                                                                           NM                                                                          Miron et al., 2005 \[[@B103-pathogens-08-00213]\]

  Israel      Experimental study                                     2005                         5000 Newborns                                                                                                           81.5--85% serum IgM 0.7% had cCMV infection                                                                                                          NM                                                                          Ziyaeyan et al., 2007 \[[@B97-pathogens-08-00213]\]

  Israel      Retrospective study                                    2005--2013                   149                                                                                                                     36% CMV infection                                                                                                                                    Severe hearing loss                                                         Bilavsky et al., 2016 \[[@B104-pathogens-08-00213]\]

  Israel      Retrospective-cohort study                             2005--2012                   210 infants with cCMV                                                                                                   75% symptomatic\                                                                                                                                     Prematurity, abnormal hearing, lenticulostriate vasculopathy                Bilavsky et al., 2015 \[[@B72-pathogens-08-00213]\]
                                                                                                                                                                                                                          25% asymptomatic                                                                                                                                                                                                                 

  Israel      Retrospective study                                    2005--2013                   284 infants with cCMV                                                                                                   69.7% symptomatic\                                                                                                                                   Hepatitis, cholestatic disease                                              Bliavsky et al., 2015 \[[@B88-pathogens-08-00213]\]
                                                                                                                                                                                                                          30.3% asymptomatic                                                                                                                                                                                                               

  Palestine   Retrospective study                                    2006--2012                   249 newborns                                                                                                            4 out of 249 newborns with cCMV born to mothers with positive CMV DNA in urine                                                                       NM                                                                          Neirukh et al., 2013 \[[@B105-pathogens-08-00213]\]

  Israel      Retrospective case-control study                       2006--2015                   138 infants with cCMV                                                                                                   66.67% positive with amniocentesis                                                                                                                   Abnormal hearing, developmental delay                                       Bilavsky et al., 2016 \[[@B106-pathogens-08-00213]\]

  Iran        Experimental study                                     2007                         92 pregnant women with caesarian section                                                                                98% of women had positive serum IgG\                                                                                                                 NM                                                                          Townsend et al., 2013 \[[@B107-pathogens-08-00213]\]
                                                                                                                                                                                                                          5.4% of women had positive serum IgM\                                                                                                                                                                                            
                                                                                                                                                                                                                          Neonates from IgG positive mothers had positive IgM                                                                                                                                                                              

  Iran        Experimental study                                     2008                         844 pregnant women                                                                                                      93% had positive serum IgG\                                                                                                                          Congenital disorders                                                        Arapour et al., 2008 \[[@B83-pathogens-08-00213]\]
                                                                                                                                                                                                                          5% had positive serum IgM                                                                                                                                                                                                        

  Israel      Observational study                                    2008                         Twenty-eight pregnant mothers primary CMV infection acquired after 25 weeks of gestation                                21 neonates had a vertical transmission with no symptoms\                                                                                            All 21 infected neonate showed clinical symptoms of CMV infection           Gindes et al., 2008 \[[@B75-pathogens-08-00213]\]
                                                                                                                                                                                                                          One pregnancy was terminated in 36 weeks with apparent symptoms                                                                                                                                                                  

  Israel      Retrospective study                                    2009                         All pregnant mothers with positive IgM & high IgG Avidity                                                               79 women with CMV IgM-high IgG avidity combination (indicate past infection)                                                                         NM                                                                          Kanengisser -Pines et al., 2009 \[[@B108-pathogens-08-00213]\]

  Israel      Retrospective study                                    2009--2010                   8105 infants                                                                                                            0.28% prevalence                                                                                                                                     CNS involvement, abnormal hearing                                           Barkai et al., 2013 \[[@B82-pathogens-08-00213]\]

  Israel      Cohort study                                           2010                         27 cCMV infected fetuses                                                                                                Temporal lobe volumes were significantly smaller in fetuses infected with CMV compared to uninfected fetuses                                         Severe brain dysmorphology in first and second trimesters.                  Hoffman et al., 2010 \[[@B74-pathogens-08-00213]\]

  Egypt       Experimental study                                     2011                         33 neonate and mothers                                                                                                  Four neonates with positive IgM, two of which had mothers with positive IgM                                                                          Gastrointestinal complications                                              Abu Faddan et al., 2011 \[[@B109-pathogens-08-00213]\]

  Israel      Prospective study behavioral studies of LSV symptoms   2011                         92 infants with congenital CMV                                                                                          50 cases had lenticulostriate vasculopathy and hearing loss.                                                                                         CNS impairment, abnormal hearing                                            Amir et al., 2011 \[[@B80-pathogens-08-00213]\]

  Israel      Retrospective study                                    2011                         Infected infants (CMV DNA positive)                                                                                     NM                                                                                                                                                   Abnormal white matter                                                       Farkas et al., 2011 \[[@B78-pathogens-08-00213]\]

  Oman        Retrospective review                                   2011--2012                   373 infants                                                                                                             34 positives cases                                                                                                                                   Death, prolonged PICU stay, respiratory complication                        Abdelmogheth et al., 2014 \[[@B90-pathogens-08-00213]\]

  Kuwait      Prevalence study-follow up until pregnancy             2013                         983 pregnant mothers                                                                                                    9% positive cord blood IgM\                                                                                                                          NA                                                                          Al-Awadhi et al., 2013 \[[@B110-pathogens-08-00213]\]
                                                                                                                                                                                                                          0.9% positive urine PCR. Seven of the nine cases had a high viral load                                                                                                                                                           

  Egypt       Cross-sectional study                                  2013                         546 pregnant women                                                                                                      100% positive serum IgG\                                                                                                                             NM                                                                          Kamel et al., 2014 \[[@B111-pathogens-08-00213]\]
                                                                                                                                                                                                                          7.3% positive serum IgM with an intermediate IgG avidity index. Of these, 50% had higher avidity indices after the 3rd trimester.                                                                                                

  Israel      Prospective cohort study                               2013                         142 pregnant women with primary CMV infection and vertical transmission in the 1st and second trimesters                The primary infection occurred in the 1st (50%) and second (50%) trimester\                                                                          Auditory damage or neurodevelopmental disabilities                          Lipitz et al., 2013 \[[@B77-pathogens-08-00213]\]
                                                                                                                                                                                                                          Seven pregnancies terminated with neurologic sequelae\                                                                                                                                                                           
                                                                                                                                                                                                                          one neonate died due to neurologic complications                                                                                                                                                                                 

  Iran        Prevalence study                                       2013--2014                   100 symptomatic infants less than 3-weeks old                                                                           58% with cCMV                                                                                                                                        Hearing loss                                                                Ebrahimi-Rad et al., 2017 \[[@B96-pathogens-08-00213]\]

  Iran        Cross-sectional study                                  2014                         225 pregnant women and their newborns                                                                                   100% of mothers had positive IgG, of which 2.7% had positive IgM\                                                                                    CMV infection by radiological evaluation (CT scan)                          Erfanianahmadpoor et al., 2014 \[[@B112-pathogens-08-00213]\]
                                                                                                                                                                                                                          Women with normal deliveries showed low IgG compared to caesarian section                                                                                                                                                        

  Israel      Retrospective study                                    2014--2015                   178 infants with hearing disability                                                                                     2.2% with cCMV                                                                                                                                       CNS symptoms                                                                Ari-Even Roith et al., 2017 \[[@B79-pathogens-08-00213]\]

  Iran        Prospective study                                      2014--2016                   1617 neonate                                                                                                            0.49% with cCMV                                                                                                                                      Short-term growth impairment                                                Karimian et al., 2016 \[[@B84-pathogens-08-00213]\]

  Sudan       Experimental study                                     2015                         50 infants                                                                                                              8% with cCMV                                                                                                                                         Congenital anomalies                                                        Ebrahimet al., 2015 \[[@B113-pathogens-08-00213]\]

  Sudan       Experimental study                                     2016                         90 pregnant women                                                                                                       98.9% had positive serum IgG\                                                                                                                        NA                                                                          Altayeb et al., 2016 \[[@B114-pathogens-08-00213]\]
                                                                                                                                                                                                                          1.1% had positive serum IgM                                                                                                                                                                                                      

  Israel      Retrospective cohort study                             2016                         98 infants from infected mothers                                                                                        52 received antiviral upon delivery                                                                                                                  Lenticulostriate vasculopathy on postnatal US, Sensorineural hearing loss   Amir et al., 2016 \[[@B71-pathogens-08-00213]\]

  Iran        Case control study                                     2016                         81 pregnant women who aborted                                                                                           Anti-CMV IgM was higher compared to controls (25.9% compared to 12.2%; OR = 12.2, *p* = 0.019)                                                       Early abortion                                                              Rasti et al., 2016 \[[@B85-pathogens-08-00213]\]

  Israel      Retrospective cohort study                             2017                         107 infants with cCMV 95 of which are from mothers with primary infection, 12 from mothers with non-primary infection   Incidence of abnormal brain sonographic findings high in infants of mothers with primary infection was 67%, compared to non-primary infection 8.3%   Infant's Mothers acquired gestational hypertensive disorder and GDM         Hadar et al., 2010 \[[@B89-pathogens-08-00213]\]

  Iraq        This prospective study                                 2019                         24 neonates                                                                                                             96% with CMV infection                                                                                                                               Jaundice-, hepatosplenomegaly                                               Alwan et al., 2019 \[[@B115-pathogens-08-00213]\]

  Iran        Pilot study                                            January 2012 to March 2012   620 infants                                                                                                             0.32% positive for CMV DNA                                                                                                                           Infected infants showed no symptoms                                         Fahimzad et al., 2013 \[[@B87-pathogens-08-00213]\]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* NM: Not mentioned; NA: Not applicable, due to the subjects being healthy individuals; cCMV: Congenital CMV; EP: Ectopic pregnancy; CNS: Central nervous system; FT: Liver function; RF: Rheumatoid factor; CT: Computed tomography; GDM: Gestational diabetes mellitus.
